Clinical research is costly, time-consuming, and complicated enough without anything going wrong. When something does, finding and fixing it often costs more than the original problem. And the longer it goes unnoticed, the more it costs. Enrollment isn’t one problem among many — it’s the precondition for having a study at all. Everything else only matters once patients are actually enrolling. That’s why spotting the signals that threaten enrollment early, and having a Plan B ready before you need it, is the difference between a delayed and a dead study.

In this webinar, hosted by MedTech Leading Voice, Daniela Karrer of Donawa Lifescience will walk through four real studies that had stalled. For each one, she will present what the sponsor actually saw, or did not see, then what turned out to be wrong underneath.

What you’ll take away:

You’ll see why choosing a site means choosing a key partner, not just a participant — and why that choice starts at the planning stage, not after enrollment stalls. You’ll understand why sending a monitor often doesn’t fix a stalled study, and what does. And you’ll know what a structured diagnosis of a struggling study actually involves, so you can tell whether one of yours needs it.

Who it’s for:

Clinical operations, regulatory, and study management teams running device or IVD trials in the US and EU. Bring the study that’s been on your mind for the Q&A session.